A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.

NCT00424502 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: rituximab [MabThera/Rituxan]
DRUG: Methotrexate

Sponsor

Hoffmann-La Roche